MGF (Mechano Growth Factor) is one of the more biologically specific compounds in research-vendor catalogues: it is not a generic growth factor but a locally-acting splice variant of the IGF-1 gene, produced inside muscle in direct response to mechanical load and damage. Its research interest is concentrated almost entirely on one event — the activation of muscle satellite cells — which makes it mechanistically distinct from systemic IGF-1 and from IGF-1 LR3. This monograph covers what MGF is, how it is thought to act, where the evidence is strong and where it is genuinely contested, and what a vendor should prove.
Chemical identity and structure.
MGF is a 24-amino-acid peptide corresponding to the C-terminal E-domain of the IGF-1Ec splice variant in humans (IGF-1Eb in rodents) — that is, the unprocessed C-terminus of an IGF-1 isoform. A pegylated, long-acting research form, PEG-MGF, is also widely sold. Native MGF has an extremely short half-life, on the order of 5–7 minutes; pegylation extends the effective half-life to roughly a day or more, which is the practical reason PEG-MGF exists.
Mechanism of action.
On mechanical stress, the IGF-1Ec precursor is transcribed and proteolytically processed, releasing the MGF E-peptide. The prevailing model assigns MGF an early, distinct role from IGF-1Ea: MGF activates quiescent satellite cells (the resident muscle stem cells), driving them from G0 into the cell cycle, promoting their proliferation while restraining premature differentiation, and inhibiting myoblast apoptosis. IGF-1Ea then dominates the later differentiation and protein-synthesis phase. The receptor through which the MGF E-peptide signals is debated — several lines of evidence suggest it acts at least partly independently of the classical IGF-1 receptor.
Research applications and the evidence base.
MGF is studied in muscle repair and hypertrophy models, satellite-cell biology, and to a lesser extent cardiac and neural repair. It is important to present this evidence honestly: the literature is genuinely mixed. Some studies report robust satellite-cell activation and fusion effects, while others — including work published in the American Journal of Physiology-Endocrinology and Metabolism — found no apparent effect of the MGF peptide on myoblasts or primary muscle stem cells, and a Frontiers review explicitly framed MGF as possibly "a loose screw" rather than an established cog in the repair machinery. The mechanistic story is attractive but not settled, and most data are preclinical or in vitro.
Human clinical trial data.
No human clinical trial has established administration parameters for MGF or PEG-MGF; VialTalk does not provide community-sourced dosing.
Storage and handling.
Store lyophilized MGF/PEG-MGF frozen (−20 °C); the dry powder is stable for long periods.
Quality and COA considerations.
A meaningful COA should confirm identity by mass spectrometry against the expected mass, report purity by HPLC (≥98% is a reasonable benchmark), and — critically for this product — make explicit whether the vial is native MGF or PEG-MGF, since the two behave completely differently and command different prices. Endotoxin testing should be reported for any injection or tissue-contact model.
Research-use note: This monograph is an educational summary of the published research literature for MGF / PEG-MGF (the IGF-1Ec E-peptide). MGF is for laboratory and research use only; the evidence for its muscle-repair effects is mixed and largely preclinical, and nothing here is medical advice.
